You are here

Article info

Article menu
Clinical trials and drug discovery
Original research
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study

Authors

  • Nan Jiang Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Beijing, ChinaKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Mengtao Li Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Beijing, ChinaKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Hongfeng Zhang Department of Rheumatology, The First Affiliated Hospital of Dalian Medical University, Dalian, China PubMed articlesGoogle scholar articles
  • Xinwang Duan Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China PubMed articlesGoogle scholar articles
  • Xiaofeng Li Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China PubMed articlesGoogle scholar articles
  • Yongfei Fang Department of Rheumatology, Southwest Hospital, Third Military Medical University, Chongqing, China PubMed articlesGoogle scholar articles
  • Hongbin Li Department of Rheumatology, The Affiliated Hospital of Inner Mongolia Medical College, Hohhot, China PubMed articlesGoogle scholar articles
  • Pingting Yang Department of Rheumatology and Immunology, First Affiliated Hospital, China Medical University, Shenyang, China PubMed articlesGoogle scholar articles
  • Hui Luo Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China PubMed articlesGoogle scholar articles
  • Yanhong Wang Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Liying Peng Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Beijing, ChinaKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Jiuliang Zhao Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Beijing, ChinaKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Chanyuan Wu Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Beijing, ChinaKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Qian Wang Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Beijing, ChinaKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Xinping Tian Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Beijing, ChinaKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Yan Zhao Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Beijing, ChinaKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Xiaofeng Zeng Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaNational Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Beijing, ChinaKey Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Mengtao Li; mengtao.li{at}cstar.org.cn; Dr Xiaofeng Zeng; zengxfpumc{at}163.com
View Full Text

Citation

Jiang N, Li M, Zhang H, et al
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study
Lupus Science & Medicine 2022;9:e000617. doi: 10.1136/lupus-2021-000617

Publication history

  • Received November 14, 2021
  • Accepted December 20, 2021
  • First published January 3, 2022.
Online issue publication 
May 08, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.